Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Not refereed |
Title | Optimal Dose of Intravenous Cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: a retrospective cohort study of J-CANVAS. |
Journal | Formal name:Modern rheumatology ISSN code:14397609/14397595 |
Domestic / Foregin | Foregin |
Papers・Author | Sofue Hideaki, Kida Takashi, Hirano Aiko, Omura Satoshi, Kadoya Masatoshi, Nakagomi Daiki, Abe Yoshiyuki, Takizawa Naoho, Nomura Atsushi, Kukida Yuji, Kondo Naoya, Yamano Yasuhiko, Yanagida Takuya, Endo Koji, Hirata Shintaro, Matsui Kiyoshi, Takeuchi Tohru, Ichinose Kunihiro, Kato Masaru, Yanai Ryo, Matsuo Yusuke, Shimojima Yasuhiro, Nishioka Ryo, Okazaki Ryota, Takata Tomoaki, Ito Takafumi, Moriyama Mayuko, Takatani Ayuko, Miyawaki Yoshia, Ito-Ihara Toshiko, Yajima Nobuyuki, Kawaguchi Takashi, Fujioka Kazuki, Fujii Wataru, Seno Takahiro, Wada Makoto, Kohno Masataka, Kawahito Yutaka. |
Publication date | 2023/10 |
Papers・Description | OBJECTIVES: To identify the optimal dose of intravenous cyclophosphamide (IVCY) for induction therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: We retrospectively assessed patients with AAV who received IVCY every 2-3 weeks during the remission induction phase. The associations of the IVCY dose with infection-free survival and relapse-free survival were analysed using a Cox regression model. We compared patients in three categories: very low-dose (VLD), low-dose (LD), and conventional dose (CD) (<7.5 mg/kg, 7.5-12.5 mg/kg, and >12.5 mg/kg, respectively). The non-linear association between IVCY dose and the outcomes were also evaluated. |